How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,536 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

11501. Zinc supplementation in malnourished children with persistent diarrhea in Pakistan. (Abstract)

the two groups for hemoglobin, serum albumin, prealbumin, and plasma insulin-like growth factor-1 increments during the course of therapy. Evaluation of primary and secondary outcome criteria among the subset of children with plasma zinc levels <60 microg/d at admission did not reveal any significant differences.Although there was satisfactory recovery in malnourished children with persistent diarrhea receiving the Khitchri-yogurt diet, there was no evidence of improved weight gain or acceleration (...) for 14 days of inpatient supervised rehabilitation.overall weight gain by day 14.overall energy intake, stool output, time to diarrheal recovery and weight gain (>/=3 days), plasma zinc, copper, prealbumin, and insulin-like growth factor-1.Of 87 children randomized for supplementation with either zinc or placebo, the two groups were comparable at admission in terms of severity and duration of diarrhea, as well as nutritional and anthropometric parameters. The overall weight gain, stool volume, stool

1999 Pediatrics Controlled trial quality: predicted high

11502. [Effect of racecadotril in the management of acute diarrhea in infants and children]. (Abstract)

with rehydration alone in children aged three months to three years who had acute diarrhoea and were evaluated in the emergency department (ED). The primary end point was the number of medical exams during the week after starting treatment. Secondary end points were the number of stools during the first 48 hours, the duration of the diarrhoea and the weight on day 7.One hundred and sixty-six children were alternatively randomized to the treated and the control groups. There was no difference for age, degree (...) [Effect of racecadotril in the management of acute diarrhea in infants and children]. The treatment of diarrhoea relies on the maintenance or restoration of hydration with maintenance of an adequate nutritional intake. Racecadotril has been shown to reduce the stools output during acute diarrhoea. The present work was aimed at measuring the number of emergency department visits for acute diarrhoea either the children received racecadotril or not.Racecadotril and rehydration were compared

2002 Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie Controlled trial quality: uncertain

11503. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. (Abstract)

in two community teaching hospitals receiving metronidazole for empiric treatment of presumptive CDAD. A database including antibiotic usage, fever, white blood cell count, feeding formula usage, comorbidity, and response to therapy was maintained.Seventy-one patients on the medical (50), surgical (18), obstetric (two), and trauma (one) service were identified. Sixty-two had nosocomial diarrhea; nine had diarrhea on admission. Seventy (97%) received antibiotics; one (3%) was on nelfinavir only (...) . Eighteen (25%) were subsequently proven to have CDAD; two (3%) had laxative-induced diarrhea; two (3%) had diarrhea secondary to a medication (colchicine [one] and nelfinavir [one]); one (1%) had diarrhea caused by bowel preparation for colonoscopy. The remaining 49 (68%) did not have a clearly established diarrhea etiology. (Four did not undergo stool examination.) Statistical analysis (chi(2) test) demonstrated a significant decrease in symptoms for metronidazole-treated patients with CDAD versus

2003 American Journal of Gastroenterology

11504. Drug Abuse - Unusual Presentations

Drug Abuse - Unusual Presentations Abuse of Drugs - Unusual Presentation. Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Drug Misuse - Unusual Presentations Authored by , Reviewed by | Last edited 1 Mar 2019 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence (...) . Signs of drug-associated illnesses (eg, , , ). Medical conditions presenting in drug misusers Patients may present with a variety of medical conditions but the doctor may not be aware of the history of drug dependency. The following is a list of scenarios: Patient found unconscious - consider narcotics, barbiturates, solvents and benzodiazepine as well as alcohol (see also and ). - consider methylenedioxymethamfetamine (MDMA, or 'ecstasy'), lysergic acid diethylamide (LSD), amfetamine, anabolic

2008 Mentor

11505. Drug Eruptions

is to blame, especially if they are on multiple medication. Take note of all medication, including prescribed, over-the-counter (OTC), 'alternative' and illicit drugs. It is not only prescription-only medications (POMs) that can cause trouble and patients may be surprised to learn that OTC products, 'natural therapies' and illegal drugs can also have adverse effects. Urticaria may not be due to a drug at all but the ingestion of strawberries or shellfish. There may be a viral infection. Has the patient (...) Drug Eruptions Drug Eruptions. Medical information about Drug Eruptions. Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Drug Allergy Authored by , Reviewed by | Last edited 24 Nov 2014 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European

2008 Mentor

11506. Antifibrinolytic Drugs and Haemostatics

Antifibrinolytic Drugs and Haemostatics Antifibrinolytic Drugs and Haemostatics. Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Antifibrinolytic Drugs and Haemostatics Authored by , Reviewed by | Last edited 30 Dec 2016 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based (...) system (IUS) or combined oral contraceptive (COC) pill. It is an effective treatment, reducing blood loss on average by 40-50% but should be discontinued if a woman's menstrual symptoms are not improving after three cycles. Non-steroidal anti-inflammatory drugs may be preferred if dysmenorrhoea is also predominant. It appears to be less effective and with greater side-effects than the intrauterine system (IUS) or endometrial resection, although pharmaceutical treatments for menorrhagia are preferred

2008 Mentor

11507. Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)

to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy). Drug: Azathioprine (AZA) AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day Other Name: Imuran Drug: Placebo infusion Placebo to IFX intravenous (IV) infusion Experimental: IFX/AZA IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were (...) intravenous (IV) infusion dosed at 5mg/kg of body weight Other Name: Remicade Drug: Azathioprine (AZA) AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day Other Name: Imuran Experimental: Intermittent IFX (during Part 2) Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy

2007 Clinical Trials

11508. Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma

) S-1 80mg/m2, 4weeks on followed by 2 weks off Other Name: S-1 alone Outcome Measures Go to Primary Outcome Measures : progression-free survival [ Time Frame: 6 months ] Secondary Outcome Measures : Anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors [ Time Frame: 6 months ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision (...) : January 23, 2009 Sponsor: Eastern Network of Cancer Immunological Therapy, Japan Information provided by: Eastern Network of Cancer Immunological Therapy, Japan Study Details Study Description Go to Brief Summary: A randomized controlled study is conducted on unresectable advanced gastric carcinoma and recurrent gastric carcinoma to compare TS-1 therapy with TS-1 + PSK therapy. The primary endpoint of this study is progression-free survival (PFS), with secondary endpoints of anticancer effect, time

2007 Clinical Trials

11509. Comparison of home-based therapy with ready-to-use therapeutic food with standard therapy in the treatment of malnourished Malawian children: a controlled, clinical effectiveness trial. Full Text available with Trip Pro

, defined as reaching a weight-for-height z score > -2, and relapse or death were the primary outcomes. The rate of weight gain and the prevalence of fever, cough, and diarrhea were the secondary outcomes.Children who received home-based therapy with RUTF were more likely to achieve a weight-for-height z score > -2 than were those who received standard therapy (79% compared with 46%; P < 0.001) and were less likely to relapse or die (8.7% compared with 16.7%; P < 0.001). Children who received home-based (...) therapy with RUTF had greater rates of weight gain (3.5 compared with 2.0 g . kg(-1) . d(-1); difference: 1.5; 95% CI: 1.0, 2.0 g . kg(-1) . d(-1)) and a lower prevalence of fever, cough, and diarrhea than did children who received standard therapy.Home-based therapy with RUTF is associated with better outcomes for childhood malnutrition than is standard therapy.

2005 The American journal of clinical nutrition Controlled trial quality: uncertain

11510. Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

: OBJECTIVES: Primary To compare the efficacy of calcium aluminosilicate anti-diarrheal (CASAD) versus placebo in reducing the incidence of grade 3 or 4 diarrhea in patients with metastatic colorectal cancer receiving an irinotecan-based chemotherapy regimen. Secondary To compare stools per day in patients treated with these drugs. To compare chemotherapy dose reductions and delays due to diarrhea in patients treated with these drugs. To compare quality of life of patients treated with these drugs (...) . To compare the safety of these drugs in these patients. To compare the incidence of grade 3 or 4 diarrhea in patients treated with these drugs. OUTLINE: This is a multicenter study. Patients are stratified according to chemotherapy regimen (irinotecan hydrochloride in combination with fluorouracil and/or biologic therapy vs irinotecan hydrochloride alone). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6

2008 Clinical Trials

11511. Drug induced lymphocytic colitis. Full Text available with Trip Pro

Drug induced lymphocytic colitis. Three cases are presented of lymphocytic colitis with chronic diarrhoea concurrent with longterm use of Cyclo 3 Fort, a phlebotonic drug used in France. The histological and immunopathological features of lymphocytic colitis are described. We show that lymphocytic colitis is drug induced, particularly in one patient where the immunopathological features of mucosal immune cell activation were induced by drug rechallenge. It is concluded that lymphocytic colitis (...) may be drug induced, secondary to a chronic activation of the mucosal immune system by one or several components of the drug.

1994 Gut

11512. Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

the effects. Abuse alcohol and other drugs. Are pregnant. Have a condition which interferes with intestinal absorption, such as severe diarrhea. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006441 Locations Layout table for location information (...) Institute of Allergy and Infectious Diseases (NIAID) Collaborators: Chiron Corporation Agouron Pharmaceuticals Glaxo Wellcome Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID) Study Details Study Description Go to Brief Summary: The purpose of this study is to see whether taking interleukin-2 (IL-2) and other anti-HIV drugs affects the course of HIV disease in patients with primary HIV infection (the time period that immediately follows infection

2000 Clinical Trials

11513. Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients

medical interviews and physical exams, sigmoidoscopy with mucosal biopsy, and blood tests. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 14 participants Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double Primary Purpose: Treatment Official Title: Impact of Co-Receptor and HIV Viral Burden on Gut Mucosa Study Start Date : October 1999 Resource links provided by the National Library of Medicine related topics (...) Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect

2003 Clinical Trials

11514. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). (Abstract)

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). A multi-centric trial was performed to explore the clinical activity, in terms of response and toxicity (primary objectives), duration of response and survival (secondary objectives), of docetaxel with cisplatin in advanced gastric cancer (AGC).Patients with measurable unresectable and/or metastatic gastric (...) of 56% (95% CI: 41%-71%). Twelve patients had stable disease for > or = 9 weeks (3 cycles). The median time to progression and overall survival were 6.6 and 9 months, respectively. Grade > or = 3 toxicities were neutropenia 81%, anemia 32%, thrombocytopenia 4%, alopecia 36%, fatigue 9%, mucositis 9%, diarrhea 6%, nausea/vomiting 4%, neurologic 2%, and one anaphylaxis precluding treatment administration. We recorded nine episodes of non-fatal febrile neutropenia in eight patients, two of them

2000 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Controlled trial quality: uncertain

11515. TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

active or underlying gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease Currently significant diarrhea, gastric stasis, or constipation that in the investigator's opinion could influence drug absorption or bioavailability Any history of significant skin disease. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study (...) : Completed First Posted : August 26, 2008 Last Update Posted : April 18, 2013 Sponsor: Tibotec Pharmaceuticals, Ireland Information provided by (Responsible Party): Tibotec Pharmaceuticals, Ireland Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the interactions seen when somebody doses with TMC435350 and Rifampin (commercial form of antibiotic). Condition or disease Intervention/treatment Phase Hepatitis C HCV Tuberculosis Rifampin Pharmacokinetics Drug

2008 Clinical Trials

11516. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. (Abstract)

eradication/presumed eradication following monotherapy was 85/102 (83%) for ciprofloxacin and 31/46 (67%) for standard-treated patients (95% CI = 1.6% to 30.3%), and that for combination therapy was 29/36 (81%) for ciprofloxacin and 7/10 (70%) for standard-treated patients (95% CI = -18.3% to 39.5%). Drug-related adverse events, primarily diarrhoea and nausea, were reported in 22% of ciprofloxacin-treated patients and 20% of standard-treated patients. In summary, ciprofloxacin administered alone (...) Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. Five hundred and forty patients with severe infection were enrolled in a multicentre, prospective, randomized, non-blinded study to compare the efficacy and safety of i.v. ciprofloxacin with i.v. standard therapy. Five hundred and thirty-one patients received at least one dose of study drug for pneumonia (310), septicaemia (112

1999 The Journal of antimicrobial chemotherapy Controlled trial quality: uncertain

11517. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. (Abstract)

), and diarrhea (5% cinacalcet, 2% control).Treatment with cinacalcet is a safe and effective therapy for long-term control of secondary hyperparathyroidism. 1-year therapy with cinacalcet was associated with sustained, clinically significant reductions in calcium, Ca x P and iPTH which allowed a greater percentage of patients to achieve NKF-KDOQI target goals for PTH and Ca x P. (...) Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. This 1-year double-blind, placebo-controlled, multicenter study evaluated the long-term safety and efficacy of cinacalcet for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis.Patients were randomly assigned in a 1:1 ratio to cinacalcet or control treatment groups. The initial dose of cinacalcet (or matching placebo) was 30 mg. Doses

2007 Clinical nephrology Controlled trial quality: uncertain

11518. Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus

Albina de Patino Study Details Study Description Go to Brief Summary: Nitazoxanide has proved an cytoprotective effect against rotavirus infection. How it could be clinically important in time of hospitalization and reduction of duration of diarrhea secondary to rotavirus? Condition or disease Intervention/treatment Phase Diarrhea Rotavirus Infection Drug: Nitazoxanide Drug: Probiotic mix preparation Other: Oral hydration solutions Not Applicable Detailed Description: Nitazoxanide has demonstrated (...) Other Names: Rehsal 60 2.5% Glucosaline Outcome Measures Go to Primary Outcome Measures : Duration of diarrhea [ Time Frame: Hours ] Secondary Outcome Measures : Duration of hospitalization [ Time Frame: hours ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may

2008 Clinical Trials

11519. Efficacy of Loperamide in Treating Patients for C. Difficile Colitis and Diarrheal Disease of Unknown Cause Associated With Antibiotic Therapy

and Diarrheal Disease of Unknown Cause Associated With Prior Antibiotic Therapy. Study Start Date : October 2007 Actual Primary Completion Date : December 2013 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: A Loperamide Drug: loperamide 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd Placebo Comparator: B Placebo Drug: placebo 4 mg PO initially and 2 mg after each (...) and negative patients will be included. Condition or disease Intervention/treatment Phase Antibiotic-Associated Diarrhea Clostridium Difficile Drug: loperamide Drug: placebo Phase 4 Detailed Description: Colitis due to Clostridium difficile has been increasingly recognized as a serious nosocomial problem. Recommended therapy is with metronidazole, 500 mg four times daily for 10 days. About 80% of patients respond to this therapy. However, the response may be be delayed, in which case debilitation due

2007 Clinical Trials

11520. Efficacy of Zinc Therapy in Acute Diarrhoea in Young Children

2006 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : Preventive effect of zinc therapy on diarrhoea during the subsequent three month 14 days of enrollment Assess the acceptability of zinc therapy during diarrhoea in young children. Secondary Outcome Measures : Compare the duration of current episode in two groups receiving 5 d vs 10 d zinc. Compare the proportion of children (...) by International Centre for Diarrhoeal Disease Research, Bangladesh: ZINC SUPPLEMENTATION ACUTE DIARRHOEA UNDER FIVE CHILDREN RURAL BANGLADESH Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Signs and Symptoms, Digestive Signs and Symptoms Zinc Trace Elements Micronutrients Nutrients Growth Substances Physiological Effects of Drugs

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>